Incyte Corporation - Common Stock (NQ:INCY)

113.44 +0.71 (+0.63%)

Delayed Quote Updated: 4:00 PM EDT, Oct 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

29 30 Next >

Stay informed with the top movers within the S&P500 index on Monday. ↗

November 03, 2025

Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Monday.

Via Chartmill

Kenvue, IDEXX Laboratories, Freshpet And Other Big Stocks Moving Higher On Monday ↗

November 03, 2025

Via Benzinga

These S&P500 stocks have an unusual volume in today's session ↗

November 03, 2025

Discover the S&P500 stocks that are experiencing unusual trading volume in today's session. Find out more about these stocks below.

Via Chartmill

Earnings Scheduled For October 28, 2025 ↗

October 28, 2025

Via Benzinga

Exploring Incyte's Earnings Expectations ↗

October 27, 2025

Via Benzinga

Exploring the top movers within the S&P500 index during today's session. ↗

November 03, 2025

Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.

Via Chartmill

Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting

November 03, 2025

From Incyte

Via Business Wire

Incyte to Present at Upcoming Investor Conferences

October 30, 2025

From Incyte

Via Business Wire

INCY Q3 Deep Dive: Strong Product Momentum and Pipeline Reshaping Amid Strategic Refocus

October 29, 2025

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 20% year on year to $1.37 billion. Its non-GAAP profit of...

Via StockStory

Incyte Delivers Robust Growth, But 2028 Patent Expiry Still Looms ↗

October 28, 2025

Incyte Q3 revenue rose 20% to $1.37 billion, topping estimates, as Jakafi and Niktimvo fueled growth and the company raised its 2025 revenue outlook.

Via Benzinga

Topics Intellectual Property

These S&P500 stocks have an unusual volume in today's session ↗

October 28, 2025

Curious about which S&P500 stocks are generating unusual volume on Tuesday? Find out below.

Via Chartmill

Why Incyte (INCY) Stock Is Trading Lower Today

October 28, 2025

Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 4.2% in the morning session after the company reported underwhelming third-quarter 2025 financial results.

Via StockStory

Nasdaq 100 Hits 26,000, Gold Falls Below $4,000: What's Moving Markets Tuesday? ↗

October 28, 2025

Tech stocks hit new highs as the Nasdaq 100 rallies 0.7% midday. Investors eye a Fed rate cut, Trump-Xi meeting, and major tech earnings.

Via Benzinga

Topics Economy

Incyte (INCY) Q3 2025 Earnings Call Transcript ↗

October 28, 2025

Incyte (INCY) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Incyte Falls After Hiked 2025 Outlook Misses Wall Street's Bullish Views ↗

October 28, 2025

The company delivered significantly better-than-expected third-quarter sales and earnings, but shares took a premarket hit.

Via Investor's Business Daily

Topics Government

Incyte Corp (NASDAQ:INCY) Reports Strong Q3 2025 Earnings, Beating Estimates ↗

October 28, 2025

Incyte (INCY) Q3 2025 earnings beat expectations with $1.37B revenue and $2.26 EPS. Driven by Jakafi and Opzelura growth, the company also raised its full-year 2025 guidance.

Via Chartmill

Topics Earnings

Incyte (NASDAQ:INCY) Reports Strong Q3

October 28, 2025

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 20% year on year to $1.37 billion. Its non-GAAP profit of $2.26 per share...

Via StockStory

Topics Artificial Intelligence

Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates

October 28, 2025

From Incyte

Via Business Wire

Incyte and Enable Injections Announce Strategic Partnership for enFuse® On-Body Delivery System

October 27, 2025

From Incyte and Enable Injections

Via Business Wire

What To Expect From Incyte’s (INCY) Q3 Earnings

October 26, 2025

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting earnings this Tuesday morning. Here’s what you need to know.

Via StockStory

Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis

October 25, 2025

From Incyte

Via Business Wire

Eli Lilly's New Ebglyss Results Back Flexible Treatment Options For Atopic Dermatitis ↗

October 24, 2025

Eli Lilly reports new data showing sustained efficacy for Ebglyss with less frequent dosing and strong long-term results for Olumiant in hair regrowth.

Via Benzinga

INCYTE CORP (NASDAQ:INCY) Presents a Value Investing Opportunity with Strong Fundamentals ↗

October 22, 2025

INCYTE CORP (INCY) appears undervalued with strong profitability and a healthy balance sheet. Its low P/E and high ROE suggest a potential value investing opportunity.

Via Chartmill

These S&P500 stocks are gapping in today's session ↗

October 20, 2025

Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Monday. Discover the gap up and gap down stocks in the S&P500 index.

Via Chartmill

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma

October 19, 2025

From Incyte

Via Business Wire

Incyte (INCY) Stock Is Up, What You Need To Know

October 16, 2025

Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) jumped 1.5% in the afternoon session after the company announced Health Canada's approval of its Opzelura cream for treating atopic...

Via StockStory

Topics Artificial Intelligence

Incyte's (INCY) EVP and General Counsel Sold 4,100 Shares for $352,000 ↗

October 14, 2025

Via The Motley Fool

Topics Regulatory Compliance

Data from Incyte’s TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025

October 12, 2025

From Incyte

Via Business Wire

JPMorgan Elevates Incyte Price Target Amidst Robust Pipeline and Commercial Success, Yet Maintains Cautious "Neutral" Stance

October 10, 2025

JPMorgan Chase & Co. (NYSE: JPM) has recently recalibrated its outlook on the biopharmaceutical giant Incyte Corporation (NASDAQ: INCY), with a notable upward revision of its price target for the...

Via MarketMinute

Topics Economy Intellectual Property

What 14 Analyst Ratings Have To Say About Incyte ↗

October 09, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

29 30 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.